REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Clinical trial NCT03610711 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03610711
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-06
- Primary completion
- 2026-12-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.